Bachelor of clinical medicine, Mudanjiang Medical College; Master of neurophysiology, Jilin University; Doctor of neuroscience, University of Ruhr Bochum, Germany; Neuropharmacology expert; Leading talents of Beijing's "overseas high-level talent gathering project"; Beijing distinguished expert

Bachelor of clinical medicine, Bethune Medical University; Master of Cardiology, China Medical University; Doctor of science, Jilin university student; Doctor of medicine, University of Giessen, Germany; Postdoctoral Fellow, Graz Medical University, Austria; Cardiovascular pharmacologist; Leading talents of Beijing's "overseas high-level talent gathering project"; Beijing distinguished expert; Innovative talents in Jiangsu Province

Master of East China University of technology; Senior Sales Manager of waters east China; More than 15 years sales experience

Doctor, Institute of Biophysics, Chinese Academy of Sciences; More than 15 years experience in new drug screening and R & D

Chairman of Rongke Technology (300290), a former listed company; good at enterprise listing, enterprise investment and financing, M & A and fund management.

The chief supervisor of a listed company, with more than 20 years of financial work experience, is familiar with the operation of the capital market.

Professor, Nanyang University of technology, Singapore; Professor, University of California Irvine; One of the world's top experts in ion channel drug research and development, with more than 150 articles published in top journals such as nature, science and Journal of clinical investigation; It focuses on the transformation research plan of potassium channel targeted therapy for autoimmune, vascular fibrosis and infectious diseases. At present, it has applied for 16 new drug invention patents. Professor George chandy first discovered Kv1 The 3-channel blocker shk-186 (dalazatide) has completed the clinical phase I B trial.